
Avinger, Inc. – NASDAQ:AVGR
Avinger stock price today
Avinger stock price monthly change
Avinger stock price quarterly change
Avinger stock price yearly change
Avinger key metrics
Market Cap | 1.55M |
Enterprise value | 6.50M |
P/E | -0.19 |
EV/Sales | 0.52 |
EV/EBITDA | -0.26 |
Price/Sales | 0.38 |
Price/Book | 1.14 |
PEG ratio | N/A |
EPS | -17.43 |
Revenue | 7.62M |
EBITDA | -16.7M |
Income | -16.75M |
Revenue Q/Q | -1.53% |
Revenue Y/Y | -7.85% |
Profit margin | -109.34% |
Oper. margin | -198.58% |
Gross margin | 31.2% |
EBIT margin | -198.58% |
EBITDA margin | -219.07% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAvinger stock price history
Avinger stock forecast
Avinger financial statements
Jun 2023 | 2.04M | -4.17M | -204.61% |
---|---|---|---|
Sep 2023 | 1.81M | -2.04M | -112.27% |
Dec 2023 | 1.90M | -5.02M | -263.59% |
Mar 2024 | 1.85M | -5.51M | -296.77% |
Sep 2025 | 3.5M | -486.4K | -13.9% |
---|---|---|---|
Oct 2025 | 3.5M | -561.26K | -16.04% |
Dec 2025 | 3.9M | -139.6K | -3.58% |
Dec 2025 | 4M | -251.09K | -6.28% |
Analysts Price target
Financials & Ratios estimates
Payout ratio | 0% |
---|
2019 | 78.74% |
---|---|
2020 | 17.85% |
2021 | 9.82% |
2022 | 66.54% |
2023 |
Jun 2023 | 16943000 | 23.53M | 138.9% |
---|---|---|---|
Sep 2023 | 17844000 | 19.19M | 107.59% |
Dec 2023 | 13770000 | 19.97M | 145.04% |
Mar 2024 | 16860000 | 20.91M | 124.05% |
Jun 2023 | -3.30M | 0 | 58K |
---|---|---|---|
Sep 2023 | -3.53M | -8K | 5.13M |
Dec 2023 | -3.38M | 0 | -61K |
Mar 2024 | -4.73M | 0 | 6.63M |
Avinger alternative data
Aug 2023 | 71 |
---|---|
Sep 2023 | 71 |
Oct 2023 | 71 |
Nov 2023 | 71 |
Dec 2023 | 71 |
Jan 2024 | 71 |
Feb 2024 | 71 |
Mar 2024 | 68 |
Apr 2024 | 68 |
May 2024 | 68 |
Jun 2024 | 68 |
Jul 2024 | 68 |
Avinger other data
Period | Buy | Sel |
---|---|---|
Mar 2023 | 0 | 223 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | SUBAINATI NABEEL PAUL officer: Vice President, Finance | Common Stock | 223 | $0.81 | $181 | ||
Option | SUBAINATI NABEEL PAUL officer: Vice President, Finance | Restricted Stock Units | 417 | N/A | N/A | ||
Option | SUBAINATI NABEEL PAUL officer: Vice President, Finance | Common Stock | 417 | N/A | N/A | ||
Option | PATEL HIMANSHU officer: Chief Te.. | Restricted Stock Units | 834 | N/A | N/A | ||
Option | PATEL HIMANSHU officer: Chief Te.. | Common Stock | 834 | N/A | N/A | ||
Option | SOINSKI JEFFREY M director, officer.. | Restricted Stock Units | 1,250 | N/A | N/A | ||
Option | SOINSKI JEFFREY M director, officer.. | Common Stock | 1,250 | N/A | N/A | ||
Option | ELIAS TAMARA director | Restricted Stock Units | 2,250 | N/A | N/A | ||
Option | ELIAS TAMARA director | Common Stock | 2,250 | N/A | N/A | ||
Sale | CULLEN JAMES director | Common Stock | 184 | $0.57 | $105 |
Patent |
---|
Application Filling date: 20 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 18 May 2022 Issue date: 1 Sep 2022 |
Grant Utility: Atherectomy catheters with imaging Filling date: 15 Mar 2013 Issue date: 9 Aug 2022 |
Application Filling date: 22 Feb 2022 Issue date: 4 Aug 2022 |
Grant Filling date: 1 Oct 2018 Issue date: 2 Aug 2022 |
Grant Utility: Atherectomy catheter Filling date: 2 Jul 2019 Issue date: 12 Jul 2022 |
Application Filling date: 22 Dec 2021 Issue date: 16 Jun 2022 |
Application Filling date: 17 Feb 2022 Issue date: 2 Jun 2022 |
Grant Filling date: 1 Jun 2017 Issue date: 31 May 2022 |
Application Filling date: 4 Oct 2021 Issue date: 28 Apr 2022 |
Quarter | Transcript |
---|---|
Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 20 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Jeffrey M. Soinski (1962) Pres, Chief Executive Officer & Director | $504,900 |
Mr. Himanshu N. Patel (1960) Chief Technology Officer | $359,440 |
Mr. Mark B. Weinswig (1973) Chief Financial Officer | $359,440 |
-
What's the price of Avinger stock today?
One share of Avinger stock can currently be purchased for approximately $0.73.
-
When is Avinger's next earnings date?
Unfortunately, Avinger's (AVGR) next earnings date is currently unknown.
-
Does Avinger pay dividends?
No, Avinger does not pay dividends.
-
How much money does Avinger make?
Avinger has a market capitalization of 1.55M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 7.51% to 7.65M US dollars.
-
What is Avinger's stock symbol?
Avinger, Inc. is traded on the NASDAQ under the ticker symbol "AVGR".
-
What is Avinger's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Avinger?
Shares of Avinger can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Avinger's key executives?
Avinger's management team includes the following people:
- Mr. Jeffrey M. Soinski Pres, Chief Executive Officer & Director(age: 63, pay: $504,900)
- Mr. Himanshu N. Patel Chief Technology Officer(age: 65, pay: $359,440)
- Mr. Mark B. Weinswig Chief Financial Officer(age: 52, pay: $359,440)
-
How many employees does Avinger have?
As Jul 2024, Avinger employs 68 workers.
-
When Avinger went public?
Avinger, Inc. is publicly traded company for more then 10 years since IPO on 30 Jan 2015.
-
What is Avinger's official website?
The official website for Avinger is avinger.com.
-
Where are Avinger's headquarters?
Avinger is headquartered at 400 Chesapeake Drive, Redwood City, CA.
-
How can i contact Avinger?
Avinger's mailing address is 400 Chesapeake Drive, Redwood City, CA and company can be reached via phone at +65 02417900.
Avinger company profile:

Avinger, Inc.
avinger.comNASDAQ
71
Medical - Instruments & Supplies
Healthcare
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Redwood City, CA 94063
CIK: 0001506928
ISIN: US0537348775
CUSIP: 053734604